The U.S. Food and Drug Administration (FDA) has approved Phesgo, an under-the-skin injection of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, as a faster and more convenient alternative to treat people with HER2-positive breast cancer. The approval of this fixed-dose combination is for use with chemotherapy in early and metastatic breast cancers, the same indications for which the combination of intravenous (into-the-vein) Herceptin and Perjeta is approved. The original formulations required intravenous infusions given over 2.5 hours. Phesgo…
You must be logged in to read/download the full post.
The post FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers appeared first on BioNewsFeeds.